丹红注射液联合半量依达拉奉治疗急性脑梗死安全性和有效性探讨

目的探讨丹红注射液联合半量依达拉奉组成的多重神经保护治疗模式治疗急性脑梗死的安全性和有效性。方法选择发病72h内的脑梗死患者138例，完全随机分为治疗组（68例）和对照组（70例）。2组均给予奥扎格雷纳治疗及常规治疗，禁用溶栓、抗凝和降纤药物及其他自由基清除剂；治疗组加用丹红注射液20ml＋生理盐水250ml静脉滴注、1次／d，依达拉奉注射液30mg＋生理盐水100ml静脉滴注、1次／d。疗程均为14d。治疗前后对2组患者进行美国国立卫生研究院卒中量表（N1HSS）和日常生活能力（ADL）评分及治疗效果比较，观察2组药物不良反应发生情况。结果2组治疗后NIHSS评分和ADL评分差异均有统计学意义（均P〈0．05）；治疗组总有效率86．8％（59／68），对照组总有效率68．6％（48／70），2组疗效差异有统计学意义（P〈0．05）；治疗组不良事件发生率为5．8％（4／68），对照组为4．2％（3／70），2组差异无统计学意义（P〉0．05）。结论丹红注射液联合半量依达拉奉组成的多重脑保护治疗模式对急性脑梗死患者安全有效。

Safety and efficacy of Danhong injection and half dose of edaravone treating acute cerebral infarction

Objective To investigate the safety and efficacy of multiple neural protection treatment mode which consists of Danhong injection and half dose of edaravone in treating acute cerebral infarction. Methods We enrolled 138 cerebral infarction patients with onset time within 72 h and divided them into treatment group and control group. The two groups were given sodium ozagral treatment and conventional treatment; at the same time, thrombolysis, anticoagulation, reduces fiber drugs and other free radical scavenging agents were stopped. The patients of the treatment group had Danhong injection and 250 ml saline infusion, which was combined with 30 mg edaravone injection and 100 ml saline infusion everyday. One course of the treatment was 14 days. Before and after treatment, we observe the neural function defect and daily life ability to compare the efficacy and observe adverse drug reactions. Results The difference of NIHSS scores and the ADL scores between the two groups was significant （P 〈 0.05 ）. The total effective rate of the treatment group was 86.8% （59/68） and the total effective rate of the control group was 68.6% （48/70） ; the curative effect was significantly different （P 〈 O. 05 ）. The adverse events rates of the treatment group and control group respectively was 5.8% （4/68） and 4.2% （3/70） （P 〉 0.05 ）. Conclusion The multiple neural protection treatment mode which consists of Danhong injection and half dose of edaravone is safe and effective in treating acute cerebral infarction.